Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADRO

Aduro Biotech (ADRO) Stock Price, News & Analysis

Aduro Biotech logo

About Aduro Biotech Stock (NASDAQ:ADRO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.28
$14.60
52-Week Range
N/A
Volume
171,500 shs
Average Volume
162,237 shs
Market Capitalization
$236.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ADRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter.

ADRO Stock News Headlines

Aduro Clean Technologies Inc.
Trump’s biggest move, misreported
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.
ACTHD Aduro Clean Technologies Inc.
Aduro Clean Technologies Inc Ordinary Shares
PT Adaro Energy Indonesia Tbk
PT Adaro Energy Indonesia Tbk ADRO
See More Headlines

ADRO Stock Analysis - Frequently Asked Questions

Aduro Biotech, Inc. (NASDAQ:ADRO) announced its quarterly earnings data on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to analyst estimates of $8.81 million. Aduro Biotech had a negative net margin of 230.92% and a negative trailing twelve-month return on equity of 101.73%.

Aduro Biotech (ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
5/04/2020
Today
7/18/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADRO
CIK
1435049
Fax
N/A
Employees
152
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$82.37 million
Net Margins
-230.92%
Pretax Margin
N/A
Return on Equity
-101.73%
Return on Assets
-22.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.91
Quick Ratio
8.91

Sales & Book Value

Annual Sales
$17.26 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
16,212,000
Free Float
N/A
Market Cap
$236.61 million
Optionable
Optionable
Beta
0.40
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ADRO) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners